Argent Advisors’s United Therapeutics UTHR Stock Holding History

Argent Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8	Closed	–	–	481
2019 Q4	$0	Buy	+8	New	+$704	﹤0.01%	556

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Argent Advisors's UTHR Position: Q1 2020 in Review

Argent Advisors sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 8 shares.

Argent Advisors first reported a position in UTHR in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

Argent Advisors reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
Argent Advisors sold 8 United Therapeutics shares in Q1 2020.
Argent Advisors first reported a position in United Therapeutics in Q4 2019 and held it in 1 quarter.
Argent Advisors's United Therapeutics position peaked at $0 in Q4 2019.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.